title: [West syndrome: aetiology, therapeutic options, clinical course and prognostic factors].
abstract: BACKGROUND
  West syndrome is an age-specific form of epilepsy that associates infantile spasms, hypsarrhythmia and a delay in or the complete stoppage of psychomotor development, although this last case is not essential.
  
  
  OBJECTIVE
  To define the profile of West syndrome in our environment by taking into account its aetiology, semiology, response to different therapeutic options and the appearance of side effects, as well as to establish prognostic factors that determine its course.
  
  
  METHODS
  A data collection document stating the eligibility criteria was drafted. Data were collected by reviewing the medical records of patients diagnosed with West syndrome during the period between January 2003 and January 2009. Later, a statistical study was conducted with descriptive analysis and the level of statistical significance of the possible prognostic factors was established.
  
  
  RESULTS
  The study included 70 patients. There was a predominance of symptomatic aetiology, with hypoxia-ischaemia as the main cause. Regardless of the aetiology, 58% of patients responded to treatment with vigabatrine. Over 80% of patients being treated with adrenocorticotropic hormone were finally seizure-free and without hypsarrhythmia. Almost half the patients progressed to other epilepsies.
  
  
  CONCLUSIONS
  The statistically significant poor prognostic factors were: existence of a prenatal history, neonatal history, symptomatic aetiology, age of onset below 4 months, epileptic seizures before the onset of the spasms and outside the neonatal period, and delayed psychomotor development prior to the onset of the spasms.
authors.affiliation: Hospitales Universitarios Virgen del Rocio, 41013 Sevilla, Espana. elenaarceportillo@hotmail.com
authors.forename: E
authors.initials: E
authors.lastname: Arce-Portillo
authors.forename: M
authors.initials: M
authors.lastname: Rufo-Campos
authors.forename: B
authors.initials: B
authors.lastname: Munoz-Cabello
authors.forename: B
authors.initials: B
authors.lastname: Blanco-Martinez
authors.forename: M
authors.initials: M
authors.lastname: Madruga-Garrido
authors.forename: L
authors.initials: L
authors.lastname: Ruiz-Del Portal
authors.forename: R
authors.initials: R
authors.lastname: Candau Fernandez-Mensaque
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004569:Electroencephalography; D005260:Female; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000150:complications; D007223:Infant; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D013036:Spasms, Infantile / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome; D020888:Vigabatrin / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D000324:Adrenocorticotropic Hormone; D020888:Vigabatrin